Who is sponsoring NCT07252752?

NCT07252752 is sponsored by Medical University of Vienna.

What drugs are being tested in NCT07252752?

Interventions in NCT07252752: Intranasal Insulin, Placebo, Low dose insulin infusion, Placebo infusion, [11C] (+)-4-propyl-(+)-4-propyl-9-hydroxynaphthoxazine (PHNO).

What condition does NCT07252752 study?

NCT07252752 studies First Episode Psychosis (FEP).

Is NCT07252752 still recruiting?

NCT07252752 is currently not yet recruiting. Last updated 28 November 2025.

Last reviewed 2025-11-28 · How we verify

NCT07252752: DIPS

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Dopamine and Insulin in Psychosis

Not yet recruiting NA Last updated 28 November 2025

What this trial tests

NA trial testing Intranasal Insulin in First Episode Psychosis (FEP) in 46 participants. Not yet recruiting.

Timeline

1 January 2026

Primary endpoint
1 January 2029

1 January 2029

Quick facts

Lead sponsor	Medical University of Vienna
Phase	NA
Status	Not yet recruiting
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	double
Primary purpose	basic science
Enrollment	46
Start date	1 January 2026
Primary completion	1 January 2029
Estimated completion	1 January 2029
Sites	1 location across Austria

Drugs / interventions tested

Intranasal Insulin — full drug profile →
Placebo
Low dose insulin infusion — full drug profile →
Placebo infusion — full drug profile →
[11C] (+)-4-propyl-(+)-4-propyl-9-hydroxynaphthoxazine (PHNO) — full drug profile →

Conditions studied

First Episode Psychosis (FEP) — all drugs for First Episode Psychosis (FEP) →

Sponsor

Medical University of Vienna

Who can join

Adults 18 to 40, any sex, with First Episode Psychosis (FEP). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Patients with schizophrenia have a high risk of developing metabolic disorders and current evidence points to an overlap in mechanisms underlying psychiatric symptoms and metabolic disturbances. The main goal of this study is to investigate effects of brain insulin on dopamine signaling and energy metabolism in patients with schizophrenia experiencing their first psychotic episode (FEP). To this end, patients with schizophrenia and healthy volunteers will undergo two \[11C\]-(+)-PHNO positron emission (PET) scans to measure the changes in dopamine receptor availability after nasally applied insulin, as well as single proton magnetic resonance spectroscopy (1H-MRS) to assess the impact of intranasal insulin on levels of glucose and glutamate in the hippocampus.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Intranasal Insulin

Trials testing the same drug.

NCT03943537 — Effects of Intranasal Insulin on Neuroimaging Markers and Cognition in Patients With Psychotic Disorders · Phase 2 · completed
NCT03632681 — Effect of Intranasal Insulin on Cognitive Processes and Appetite · NA · completed

Other recruiting trials for First Episode Psychosis (FEP)

Currently open trials in the same condition.

NCT06650943 — Nursing Intervention in Weight and Metabolic Syndrome Management in First-episode Psychosis (MetaKOP) · NA · recruiting
NCT06634446 — Self-administered COgnitive Personalized Training in Early Psychosis · NA · recruiting

Other Medical University of Vienna trials

Trials by the same sponsor.

NCT07473401 — Retinal Oxygen Metabolism in Children With Myopia · not yet recruiting
NCT07511400 — The Role of NaV1.8 in Human Pain Models · EARLY_PHASE1 · not yet recruiting
NCT07516990 — Intramuscular Injection of Mashed Parathyroid Tissue Into a Forearm During Thyroid Surgery to Prevent Permanent Postoper · NA · recruiting
NCT07496437 — Is Cross-linked Hyaluronic Acid a Biologic Alternative for Alveolar Ridge Preservation? · NA · not yet recruiting
NCT07290712 — Post-Intensive Care Syndrome - Multicentre Prospective Registry Database of the DACH Region · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07252752 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Medical University of Vienna
Last refreshed: 28 November 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07252752.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing